Amgen, Allergan clear Phase III with Herceptin biosimilar

July 21, 2016 4:00 PM

29 0

Amgen, Allergan clear Phase III with Herceptin biosimilar

Amgen ($AMGN) has big biosimilar goals for this year. Fresh off a positive FDA panel earlier this month for what could be its first approved biosimilar for Humira (adalimumab), now the biotech and partner Allergan ($AGN) have reported positive top-line Phase III data for a Herceptin (trastuzumab) biosimilar to treat breast cancer.

It’s hoping for an FDA approval this year for the Humira biosimilar, which has a Sept. 25 FDA review date. And also plans to submit to the FDA for its Avastin (bevacizumab) biosimilar, for which it reported positive Phase III data last year.

Also read: U.S. motor travel up 1.5 percent in April from year ago: DOT

Read more

To category page

Loading...